SCHEMBL209919

SCHEMBL209919

Cc1ccc(NC(=O)C(=O)N[C@H]2CCN(C=O)C[C@H]2NC(=O)OC(C)(C)C)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
KCNA3 P22001 1/20 0.33
KDM1A O60341 2/20 0.33
MAOB P27338 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAF1 P04049 1/20 0.32
NAMPT P43490 1/20 0.32
DRD2 P14416 2/20 0.32
CTSK P43235 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210826 0.90 KMT2A (0.35) KMT2AL3MBTL1PIM1PIM3PIM2
SCHEMBL210138 0.81 CCR1 (0.39) NPC1TP53MAPTNFKB1RAB9A
SCHEMBL209317 0.81 FPR2 (0.42) NAMPT
SCHEMBL207173 0.81 NAMPT (0.38) KMT2AMAPTRAB9ANAMPTHDAC1
SCHEMBL209539 0.79 NTRK1 (0.36) CKS1BSKP1SKP2
SCHEMBL208311 0.77 BCL2 (0.40) NPC1TP53RAB9ASMN1; SMN2CKS1B
SCHEMBL207795 0.77 NPC1 (0.39) L3MBTL1NPC1RAB9A
SCHEMBL209570 0.76
SCHEMBL210382 0.76 HDAC3 (0.37) KMT2AL3MBTL1NAMPTDRD2HDAC3
SCHEMBL2703679 0.74 F10 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 KMT2A 762/4885L3MBTL1 1124/4885PIM1 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.